Patents Assigned to Genexine Inc.
  • Publication number: 20250026804
    Abstract: A high-concentration formulation of hGH fusion protein containing poloxamer 188 and polysorbate 80 and uses thereof are disclosed. The formulation containing poloxamer 188 and polysorbate 80 contains a high-concentration of hGH fusion protein has significantly reduced aggregation reactions and improved storage stability. The formulation can be a liquid formulation. The hGH fusion protein includes hGH and an immunoglobulin Fc polypeptide.
    Type: Application
    Filed: October 19, 2022
    Publication date: January 23, 2025
    Applicants: Genexine, Inc., HANDOK INC.
    Inventors: Chanwoong PARK, Ki-Yong KIM
  • Publication number: 20230279069
    Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v%; and (d) a surfactant with a concentration of 0.05 to 6 w/v%. Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 7, 2023
    Applicant: Genexine, Inc.
    Inventors: Donghoon CHOI, Changyong Eun, Seong Hoon Jeong, Jun Yeul LIM
  • Publication number: 20230123454
    Abstract: The present invention relates to a fusion protein including PD-L1 protein and a modified immunoglobulin Fc region and use thereof, and since the fusion protein has significantly higher purity and production yield compared to the existing fusion protein, has a high binding affinity to PD-1, reduces the proliferation of activated T cells, inhibits the generation of cytokines generated by activated T cells, and has an effect of inhibiting the infiltration of T cells or macrophages into tissues, it can be effectively used in the treatment of immune diseases.
    Type: Application
    Filed: January 6, 2021
    Publication date: April 20, 2023
    Applicant: Genexine, Inc.
    Inventors: Young Chul SUNG, Eun Ju SHIN, Yuri HWANG, Sung Hee LEE
  • Patent number: 11357827
    Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 14, 2022
    Assignee: Genexine, Inc.
    Inventors: Moon Cheol Kang, Young Woo Choi, Donghoon Choi, Young Chul Sung
  • Publication number: 20220008515
    Abstract: The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody).
    Type: Application
    Filed: November 15, 2019
    Publication date: January 13, 2022
    Applicants: NeoImmuneTech, Inc., Genexine, Inc.
    Inventors: Seung-Woo LEE, Ji-Hae KIM, Saet-byeol JO, Han Wook PARK, Donghoon CHOI, Byung Ha LEE, Young Chul SUNG, Se Hwan YANG
  • Publication number: 20170158746
    Abstract: The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 8, 2017
    Applicant: Genexine, Inc.
    Inventors: Se Hwan YANG, Donghoon CHOI, Hye Seong LIM
  • Patent number: 9000139
    Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: April 7, 2015
    Assignee: Genexine, Inc.
    Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
  • Patent number: 8883134
    Abstract: The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: November 11, 2014
    Assignees: Handok Pharmaceuticals, Inc., Genexine, Inc.
    Inventors: Young Gyu Cho, Hye Jeong Shin, Woon Young Lee, Woo Ick Jang
  • Patent number: 8586038
    Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: November 19, 2013
    Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)
    Inventors: Sehwan Yang, Young Chul Sung
  • Patent number: 8586048
    Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 19, 2013
    Assignees: Genexine, Inc., Postech Academy-Industry Foundation
    Inventors: Sehwan Yang, Young Chul Sung
  • Patent number: 8586531
    Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: November 19, 2013
    Assignees: Genexine, Inc., Postech Academy-Industry Foundation of Phohang University of Science and Technology (Postech)
    Inventors: Sehwan Yang, Young Chul Sung
  • Patent number: 8529899
    Abstract: Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: September 10, 2013
    Assignees: Genexine, Inc., Postech Academy-Industry Foundation
    Inventors: Sehwan Yang, Young Chul Sung
  • Patent number: 7989425
    Abstract: The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of ? core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: August 2, 2011
    Assignees: Genexine Inc., Postech Foundation, Dong-A Pharm. Co., Ltd., Daewood Co., Ltd., Posco
    Inventors: Young Chul Sung, Jin-Won Youn, Se-Hwan Yang, Su-Hyung Park, Chang Geun Lee
  • Publication number: 20050287117
    Abstract: The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of ?core-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, and method for administration of the vaccine by priming with the DNA vaccines described above and boosting with the recombinant adenovirus vaccine thereby enhancing the protective immunity to Hepatitis C virus.
    Type: Application
    Filed: September 24, 2003
    Publication date: December 29, 2005
    Applicants: Genexine Inc., Postech Foundation, Dong-A Pharm. Co., Ltd., Daewood Co., Ltd, Posco
    Inventors: Young Sung, Young Sung, Jin-won Youn, Se-Hwan Yang, Su-Hyung Park, Chang Lee